Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman MD to Board Ahead of Cytisinicline NDA Resubmission

With a cytisinicline NDA resubmission on the horizon, Achieve Life Sciences has added two board members whose backgrounds sit squarely at the intersection of late-stage regulatory strategy and specialty commercial execution. Jeffrey Farrow and Reid Waldman, MD joined the board on June 2, 2026, as the company moves to build out its commercial organization ahead of a potential first approval.

Farrow brings direct launch-stage finance and strategy experience from three specialty pharma companies, Hyperion, Global Blood Therapeutics, and Tarsus Pharmaceuticals, each of which was subsequently acquired, with aggregate deal value exceeding $9 billion. He currently serves as CFO and Chief Strategy Officer at Tarsus, where he has been involved in the commercial rollout of XDEMVY (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis. For QA and regulatory leads at Achieve, his familiarity with the post-approval operational build is the more operationally relevant credential.

Waldman, founder and CEO of Veradermics (NYSE: MANE), brings a physician-operator perspective to the board. Veradermics completed an upsized IPO in February 2026, raising approximately $294.8 million in gross proceeds, followed by an additional $472 million in a follow-on offering and private placement in May 2026. His clinical background in dermatology, a specialty where nicotine dependence intersects with treatment outcomes, adds a prescriber-facing lens to board-level commercial planning.

Cytisinicline, a partial nicotinic acetylcholine receptor agonist, is positioned as the first new prescription smoking cessation therapy in nearly two decades. The NDA resubmission timeline has not been publicly specified, but the board composition signals that Achieve is structuring governance around pre-approval commercial readiness rather than deferring those decisions to post-submission. For regulatory affairs leads tracking the resubmission, the parallel build of commercial infrastructure is consistent with ICH Q10 lifecycle management principles applied at the organizational level.

The appointments also reflect a broader pattern in specialty pharma: companies with a single late-stage asset increasingly front-load board expertise in capital markets and launch execution to compress the window between approval and commercial scale-up.

The measurable checkpoint to watch is the NDA resubmission date, which will set the clock on FDA's review cycle and define the operational runway Farrow and Waldman will have to contribute before a potential launch decision.

Source: Achieve Life Sciences, Inc. via GlobeNewswire, June 2, 2026.